Emisphere Technologies, Inc. announced today the publication of a research study entitled, "Investigation of the Direct Effect of Salmon Calcitonin on Human Osteoarthritic Chondrocytes," by Nordic Bioscience in the April 5, 2010 edition of the publication BMC Musculoskeletal Disorders.
To access the article, go to: http://www.biomedcentral.com/1471-2474/11/62.
Oral salmon calcitonin, which uses Emisphere's proprietary Eligen(R) Technology, is currently being studied in osteoarthritis and osteoporosis by Novartis Pharma AG and Nordic Bioscience.
The study was conducted in vitro on cartilage samples obtained from female patients undergoing total knee arthroplasty surgery for the treatment of osteoarthritis. The article describes the growth promoting effects of salmon calcitonin on these cartilage samples. The study shows that treatment with pharmacological concentrations of calcitonin increases synthesis of both proteoglycan (proteins and sugars which interweave with collagen) and collagen type II -- the key components of articular cartilage.
Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, commented, "The research conducted by Nordic Bioscience is unique and significant as it represents the first work to look chiefly at the ability of salmon calcitonin to stimulate cartilage synthesis. These findings provide evidence to substantiate the theory that calcitonin may exert a positive effect on joint health through its dual action of promoting both bone and cartilage formation."
About Emisphere Technologies, Inc.
Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its proprietary Eligen(R) Technology. The Eligen(R) Technology can be applied to the oral route of administration as well as other delivery pathways such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is www.emisphere.com.